The therapeutic effect of a combination of CDK1 inhibitor CurE and mitotane in adrenocortical carcinoma cells achieves superior therapeutic outcomes through PANoptosis activation compared to monotherapies [103]. Here, CDK1 is linked to adrenal cortex carcinoma.